Oral Contraception

FDA okays generic Mircette; company to launch it under Kariva trademark

Published in Women's Health Weekly, May 9th, 2002

Barr Laboratories, Inc., (BRL) announced that the U.S. Food & Drug Administration (FDA) has granted final approval for its application to manufacture and market a generic version of Organon, Inc.'s, Mircette oral contraceptive.

This product was a subject of a patent challenge initiated in September 2000. The company expects to be the first to market generic Mircette and is launching the product immediately. The company plans to market the product as a branded generic using the Kariva trademark.

Mircette is a 28-tablet regimen that represents a combination of desogestrel/ethinyl estradiol and ethinyl estradiol.

"The launch of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-05-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry